Why the study?
The authors describe initial clinical experiences implanting the AVEIR VR leadless pacemaker in Kazakhstani patients, representing the first procedures using this technology in Central Asia.
Answers are grounded in this paper and cite their sources.
The AVEIR VR leadless pacemaker can be successfully and safely implanted, as demonstrated by the first case series of 5 patients in Central Asia showing satisfactory early pacing parameters and no immediate complications.
In this article, we describe our first experiences implanting the AVEIR VR leadless pacemaker (Abbott) in Kazakhstani patients, a significant step in the development of this technology in Central Asia. This case series includes five male patients, with a range of symptoms (presyncope, dizziness and dyspnoea on exertion), ranging in age from 14 to 77 years; some individuals also had comorbidities, including atrioventricular block and AF. Indications for pacing were identified in each patient. The parameters of postimplantation stimulation and the results of initial observations were recorded. The procedure was quite successful and radiographic confirmation of the location of the leadless pacemaker was obtained. All patients demonstrated clinical improvement and satisfactory pacing parameters at early follow-up. The potential of the AVEIR leadless pacemaker to minimise lead insertion complications has been demonstrated, with no immediate complications observed in the patients in this study.
No takes yet. Share an insight, caveat, or question.
Бакытжанулы et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: